• LAST PRICE
    0.2192
  • TODAY'S CHANGE (%)
    Trending Down-0.0034 (-1.5274%)
  • Bid / Lots
    0.2106/ 4
  • Ask / Lots
    0.2180/ 50
  • Open / Previous Close
    0.2280 / 0.2226
  • Day Range
    Low 0.2136
    High 0.2312
  • 52 Week Range
    Low 0.2020
    High 13.5200
  • Volume
    167,258
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.2226
TimeVolumeRUBY
09:32 ET25570.2201
09:33 ET3000.2311
09:51 ET6390.223
09:53 ET1000.2236
10:13 ET1000.225099
10:15 ET2670.225099
10:22 ET35280.2202
10:24 ET423700.22
10:29 ET25000.2207
10:40 ET1000.2252
10:56 ET1000.2229
11:00 ET4230.222899
11:07 ET2000.225099
11:12 ET7930.221128
11:23 ET29930.2208
11:30 ET1000.223
11:36 ET11620.2251
11:43 ET2000.22305
11:50 ET2000.2209
11:52 ET1010.2209
12:06 ET55240.2253
12:08 ET42580.2253
12:10 ET13000.222
12:12 ET1000.222101
12:15 ET7000.2221
12:17 ET1000.2221
12:19 ET70490.2221
12:35 ET4000.22365
12:39 ET45010.2222
12:42 ET6000.2222
12:44 ET1000.2228
12:46 ET10000.224
12:50 ET583510.2177
12:51 ET6800.21845
12:53 ET28030.2136
01:00 ET21810.2192
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRUBY
Rubius Therapeutics Inc
19.8M
-0.1x
---
United StatesNNVC
NanoViricides Inc
19.5M
-2.7x
---
United StatesAPRE
Aprea Therapeutics Inc
20.4M
-0.1x
---
United StatesNRSN
Neurosense Therapeutics Ltd
20.4M
-2.7x
---
United StatesNLTX
Neoleukin Therapeutics Inc
19.2M
-0.4x
---
United StatesCDIO
Cardio Diagnostics Holdings Inc
19.0M
0.0x
---
As of 2022-11-26

Company Information

Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

Contact Information

Headquarters
399 Binney St Ste 300CAMBRIDGE, MA, United States 02142-1038
Phone
617-679-9600
Fax
302-655-5049

Executives

Chairman of the Board
Pablo Cagnoni
President, Chief Executive Officer, Chief Operating Officer
Dannielle Appelhans
Chief Scientific Officer and Head of Research and Translational Medicine
Laurence Turka
Director
Susanne Schaffert
Independent Director
Francis Cuss

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$19.8M
Revenue (TTM)
$0.00
Shares Outstanding
90.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.35
EPS
$-2.38
Book Value
$1.99
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.